Select MDx uses insights from the measurements of two biomarkers to help determine if patients are at higher risk for prostate cancer and may benefit from a biopsy
Select MDx, also called the MDx test, is a non-invasive urine test that measures two mRNA cancer-related biomarkers (HOXC6 and DLX1). The liquid biopsy test results should be combined with patient’s clinical risk factors to make an informed decision on which one of the following steps to take next:
- Recommend a prostate for the early detection of prostate cancer, or
- Adopt a routine screening protocol for the patient as he’s not at high risk of having or developing prostate cancer
Select mdx is Included in National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer Early Detection.
Select MDx Benefits
The clinical utility of Select MDx for Prostate Cancer is well-established:
- The test can identify men who have a higher likelihood of clinically significant cancer. These patients can be recommended for biopsy, which can lead to the earlier detection and treatment of prostate cancer.
- Men who are not at higher risk of prostate cancer can avoid an unnecessary biopsy.
- The test has a negative predictive value (NPV) is 95%, which gives physicians and patients reassurance that the patient has a 95% chance of not having a Gleason score ≥7 (GS≥7)..
- The test has is very accurate in predicting high-grade prostate cancer (AUC 0.85). This significantly better than the Prostate Cancer Prevention Trial (PCPT) risk calculator version 2.1
Select MDx Presentation
Presentation by Ericka Bagi BSN, RN, Senior Medical Science Liaison at mdx Health.
Dr. Crawford on Select MDx
E. David Crawford, MD, is a Professor of Urology at the University of California, San Diego. He is an internationally renowned urologist, and the former distinguished endowed Professor of Surgery, Urology, and Radiation Oncology, and Head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus in Aurora, Colorado.
Here, Dr. Crawford discusses which patients might benefit from SelextMDx testing.
Provider FAQs About Select MDx
Select MDx is a valuable tool for risk stratification in patients with suspected prostate cancer. It aids in identifying those at higher risk of aggressive disease, helping guide further diagnostic and treatment decisions.
Select MDx is especially useful when evaluating patients with elevated PSA levels or those with clinical risk factors for prostate cancer, such as family history, ethnicity, or age.
Select MDx has demonstrated high accuracy in clinical studies. However, it’s essential to
consider individual patient factors and the local prevalence of prostate cancer when interpreting
Select MDx is a reverse transcriptase polymerase chain reaction (RT-PCR) assay that measures the urinary mRNA levels of HOXC6 and DLX1 biomarkers. Higher levels of HOXC6 and DLX1 are associated with an increased risk for clinically significant prostate cancer.
- Select MDx is a valuable tool for risk stratification in patients with suspected prostate cancer. It aids in identifying those at higher risk of aggressive disease, helping guide further diagnostic and treatment decisions.
Studies Involving Select MDx
Commercialized Blood-, Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis
In the diagnosis and prognosis of prostate cancer (PCa), the serum prostate-specific antigen test is widely used but is associated with low specificity. Therefore, blood-, urinary- and tissue-based biomarker tests have been developed, intended to be used in the diagnostic and prognostic setting of PCa. This review provides an overview of commercially available biomarker tests […]
Prospective study of diagnostic accuracy in the detection of high-grade prostate cancer in biopsy-naïve patients with clinical suspicion of prostate cancer who underwent the Select MDx test
This study aimed to externally validate the diagnostic accuracy of the Select MDx test for Significant prostate cancer (Sig PCa) (ISUP > 1), in a contemporaneous, prospective, multicenter cohort with a prostate-specific antigen (PSA) between 3 and 10 ng/ml and a non-suspicious digital rectal examination.
Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score
The risk score based on the mRNA liquid biopsy assay combined with traditional clinical risk factors identified men at risk of harboring high-grade PCa and resulted in a better patient risk stratification compared with current methods in clinical practice. Therefore, the risk score could reduce the number of unnecessary prostate biopsies.
Explore more information about the Select MDx test: